Ann: Quarterly Activity Report - 30 June 2022, page-29

You might recall that JM said net margins between direct and external distribution is actually the same, the former carries SG&A costs whilst the latter you're foregoing some gross margins, so unless you build out a whole team I'd assume it makes little sense to hire just the one guy given lack of scale.I don't know whether AU is better with external distributions or direct. Lots of med-tech companies start off with 3rd party distribution before obtaining sufficient scale then transition back into in-house gradually, note company also emphasized product labels are now clearly marked Next Science so won't suffer from the same issue they had with 3M the last time round.

That said, I don't disagree with you that it's a very valid question to ask at the upcoming webcast as to why he was chosen (brand new setup) given the many other options out there. I have a clash so also won't be able to dial in unfortunately.